LEADER 03472nam 22007455 450 001 9910903789603321 005 20241031115736.0 010 $a3-031-74346-6 024 7 $a10.1007/978-3-031-74346-7 035 $a(CKB)36443051000041 035 $a(MiAaPQ)EBC31747209 035 $a(Au-PeEL)EBL31747209 035 $a(DE-He213)978-3-031-74346-7 035 $a(EXLCZ)9936443051000041 100 $a20241031d2024 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBiorenewable Solvents for Organic Synthesis /$fby Wen-Bin Yi, Xiao Gao, Wei Zhang 205 $a1st ed. 2024. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2024. 215 $a1 online resource (56 pages) 225 1 $aSpringerBriefs in Molecular Science,$x2191-5415 311 $a3-031-74345-8 327 $a Introduction of biorenewable solvents -- Biorenewable solvents -- Cyclopentyl methyl ether (CPME) -- ?-alerolactone (GVL) -- 2-Methyl tetrahydrofuran (2-MeTHF) -- Glycerine carbonate (GC) -- Propylene Carbonate (PC) -- Cyrene -- Other solvent.-Conclusive Remarks. 330 $aIn this brief the authors introduce a series of recently developed bio-based solvents including cyclopentyl methyl ether (CPME), ?-valerolactone (GVL), 2-methyl tetrahydrofuran (2-MeTHF), propylene carbonate (PC), and cyrene. Traditional organic solvents used for organic synthesis (such as benzene, ether, chloroform) have a series drawbacks on toxicity, environmental impact, and safely related issues. In addition, the fossil fuel-derived organic solvents are not sustainable. Therefore the development of biorenewable solvents is a topic of current interest. For each of the solvents, their production, toxicity profile, renewable pathway, and their utility in organic synthesis, biosynthesis, and separation processes is discussed. The target audiences of this book are organic and medicinal chemists with interests in using green solvents. It can also be used as a reference for undergraduate and graduate courses related to organic and green chemistry. 410 0$aSpringerBriefs in Molecular Science,$x2191-5415 606 $aGreen chemistry 606 $aOrganic compounds$xSynthesis 606 $aChemistry, Organic 606 $aBioorganic chemistry 606 $aMedicinal chemistry 606 $aChemical processes 606 $aGreen Chemistry 606 $aSynthetic Chemistry Methodology 606 $aOrganic Chemistry 606 $aBioorganic Chemistry 606 $aMedicinal Chemistry 606 $aProcess Chemistry 615 0$aGreen chemistry. 615 0$aOrganic compounds$xSynthesis. 615 0$aChemistry, Organic. 615 0$aBioorganic chemistry. 615 0$aMedicinal chemistry. 615 0$aChemical processes. 615 14$aGreen Chemistry. 615 24$aSynthetic Chemistry Methodology. 615 24$aOrganic Chemistry. 615 24$aBioorganic Chemistry. 615 24$aMedicinal Chemistry. 615 24$aProcess Chemistry. 676 $a660.0286 676 $a547 700 $aYi$b Wen-Bin$0772585 701 $aGao$b Xiao$01772431 701 $aZhang$b Wei$0265725 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910903789603321 996 $aBiorenewable Solvents for Organic Synthesis$94273146 997 $aUNINA LEADER 04367nam 2200889z- 450 001 9910566472203321 005 20220506 035 $a(CKB)5680000000037658 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81110 035 $a(oapen)doab81110 035 $a(EXLCZ)995680000000037658 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aThe Prevention and Treatment of Atherosclerosis 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (150 p.) 311 08$a3-0365-3465-2 311 08$a3-0365-3466-0 330 $aThis special issue of JCM 'The Prevention and Treatment of Atherosclerosis' will walk the Readers across novel diagnostic achievements in atherosclerosis and contemporary actions towards optimizing therapy.Everything begins with diagnosis. Accurate diagnostic tools and tests are of utmost importance. Contemporary research on microparticles, non-coding RNAs, proteomic characterization, ..., offers detailed molecular characteristics of athero-thrombosis.Prevention is equally important as treatment. The impact of eating habits in prophylaxis of many pathologies, including cardiovascular disease has been documented.Then new pharmacological agents. Managing hypercholesterolemia with PCSK9 inhibitors, shown great potential in efficient lipid lowering to achieve LDL-C treatment goals, as well as reduction in cardiovascular mortality and morbidity.However, therapeutic goals accomplishment requires supervision. Arising number of data support that cardiovascular risk prediction can be improved with imaging modalities displaying atheroma: carotid plaque ultrasonography, coronary calcium score, intravascular ultrasonography, and optical coherent tomography or many others.As atherosclerosis is a progressive disease, it comes the time for more radical management, including endovascular and surgical intervention. There is field for new stent and equipment technologies, new surgical and endovascular techniques, supervision of endovascular procedures with IVUS, OCT, functional flow assessment or cell therapy.From diagnosis to risk stratification, elaborated prevention models, finally to modern and optimized therapeutic intervention. 606 $aResearch & information: general$2bicssc 610 $aacute myocardial infarction 610 $aatherosclerosis 610 $aatherosclerosis prevention 610 $acardiovascular disease 610 $acardiovascular risk 610 $acardiovascular risk factors 610 $acarotid intima-media complex 610 $acarotid plaque 610 $acigarette smoking 610 $acontrol-theoretic model 610 $acoronary artery disease 610 $aCoronary Artery Surgery Study Score 610 $acoronary computed tomography angiography 610 $adegenerative aortic stenosis 610 $aearly detection 610 $afamilial hypercholesterolemia 610 $afibrin clot 610 $afibrinolysis 610 $aFramingham 610 $agenetic screening 610 $aheart failure 610 $ahigh-risk plaque 610 $aintima media thickness 610 $aintravascular imaging 610 $alogistic growth 610 $amajor adverse cardiac and cerebral events 610 $amajor cardiac and cerebral ischemic events 610 $amales 610 $amalondialdehyde low-density lipoprotein 610 $amiR-27b 610 $amyocardial infarction 610 $an/a 610 $aperipheral artery disease 610 $aprevention 610 $aPROCAM 610 $apulse wave velocity 610 $aQRISK 610 $arisk stratification 610 $aSCORE 610 $ascores 610 $astatin 610 $astatins 610 $asubclinical atherosclerosis 610 $athromboembolism 610 $avascular resistance 610 $avitamin D 615 7$aResearch & information: general 700 $aKab?ak-Ziembicka$b Anna$4edt$01314105 702 $aKab?ak-Ziembicka$b Anna$4oth 906 $aBOOK 912 $a9910566472203321 996 $aThe Prevention and Treatment of Atherosclerosis$93031711 997 $aUNINA